Chemed Corp. 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Chemed Corporation (CHE)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Chemed operates two primary segments: VITAS Healthcare, a leading provider of hospice and palliative care services, and Roto-Rooter, a provider of plumbing, drain cleaning, excavation, and water restoration services. The company operates on a decentralized basis with significant exposure to U.S. government healthcare programs (Medicare/Medicaid) for VITAS and weather-dependent demand for Roto-Rooter.
Key Financial Metrics (2025 vs. 2024)
| Metric (in thousands, except per share) | 2025 | 2024 | Change |
|---|---|---|---|
| Service Revenues & Sales | $2,529,978 | $2,431,287 | +4.1% |
| Net Income | $265,238 | $301,999 | -12.2% |
| Diluted EPS | $18.34 | $19.89 | -7.8% |
| Operating Cash Flow | $388,272 | $417,497 | -7.0% |
| Adjusted EBITDA | $458,710 | $503,002 | -8.8% |
| Debt Outstanding | $0 | $0 | - |
| Cash & Equivalents | $74,515 | $178,350 | -58.2% |
| Available Credit Facility | $404.5 million | $404.5 million | - |
Segment Performance:
- VITAS: Revenue increased 6.5% to $1.63 billion, driven by a 5.2% increase in days-of-care and a 3.4% Medicare rate increase. Net income decreased to $204.0 million due to higher Medicare cap liabilities and legal expenses.
- Roto-Rooter: Revenue was essentially flat at $900 million. Net income decreased to $135.5 million due to increased casualty insurance expenses and higher implicit price concessions in the water restoration business.
Material Changes and Drivers
- Revenue Growth: Consolidated revenue growth was driven by VITAS volume and rate increases, offset by flat performance at Roto-Rooter.
- Profitability Decline: Net income declined primarily due to a $18.7 million increase in VITAS Medicare cap liability, higher legal settlements ($3.1 million), and increased casualty insurance costs at Roto-Rooter ($5.3 million).
- Cash Position: Cash and cash equivalents decreased by $103.8 million, largely due to significant share repurchases ($431.5 million) and dividends ($31.7 million), partially offset by operating cash flows.
- Acquisitions: VITAS acquired Covenant Care operations for $85.0 million in 2024 (impacting 2025 results). Roto-Rooter acquired one franchise in Michigan for $225,000 in 2025.
Guidance, Risks, and Unusual Items
- Cybersecurity Incident: In October 2025, VITAS experienced a cybersecurity breach involving a third-party vendor. Protected Health Information (PHI) was accessed. The company negotiated a payment to the threat actor to secure data deletion. Costs were covered by cyber insurance above a $500,000 deductible. Multiple class-action lawsuits have been filed, though the company cannot estimate potential losses.
- Regulatory Risks: VITAS faces ongoing scrutiny from CMS regarding billing practices (Targeted Probe and Educate program) and Medicare cap limitations. A $30.9 million liability for Medicare cap adjustments was recorded in 2025.
- Environmental Liability: The company maintains a $1.7 million accrual for environmental cleanup related to the 1991 sale of DuBois Chemicals, with a contingent liability up to $14.9 million.
- Outlook: Management anticipates operating income and cash flows will be sufficient to meet obligations. The company continues to evaluate capital allocation, including share repurchases and dividends.
Key Investor Verification Points
- Medicare Cap Exposure: Verify the trajectory of the Medicare cap liability, which increased significantly in 2025 ($27.2 million reduction in revenue) and could impact future margins if reimbursement rates outpace cap adjustments.
- Cybersecurity Litigation: Monitor the status of class-action lawsuits filed following the October 2025 data breach and any potential regulatory penalties from CMS or state attorneys general.
- Insurance Costs: Track the trend in casualty insurance expenses for Roto-Rooter, which rose $5.3 million in 2025, and the adequacy of self-insurance accruals.
- Capital Allocation: Assess the sustainability of the current share repurchase program ($431.5 million in 2025) given the decline in net income and cash reserves.
- Regulatory Compliance: Review updates on the CMS Special Focus Program (SFP) and its potential impact on VITAS's reputation and referral patterns.